SYDNEY, AUSTRALIA – March 27, 2019 – Immutep Limited (ASX:IMM; NASDAQ:IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announces it will provide an update on the ongoing TACTI-mel Phase 1 clinical trial and the clinical development of eftilagimod alpha (“efti” or “IMP321”) in a global webcast, including a Q&A session.
The more mature data from the TACTI-mel Phase I clinical trial of eftilagimod alpha was presented at the World Immunotherapy Congress 2019 in San Diego USA on March 5, 2019, by Dr. Fre´de´ric Triebel, Immutep’s Chief Scientific Officer and Chief Medical Officer, and will be discussed and further elaborated on in the webcast.
For further information please download PDF attached:
Download this document
